Publisher Correction: Chimeric peptide EP45 as a dual agonist at GLP-1 and NPY2R receptors
نویسندگان
چکیده
منابع مشابه
Peptide binding at the GLP-1 receptor.
The receptor for GLP-1 [glucagon-like peptide-1-(7-36)-amide] is a member of the 'Family B' of GPCRs (G-protein-coupled receptors) comprising an extracellular N-terminal domain containing six conserved cysteine residues (the N-domain) and a core domain (or J-domain) comprising the seven transmembrane helices and interconnecting loop regions. According to the two-domain model for peptide binding...
متن کاملNovel GLP-1 Fusion Chimera as Potent Long Acting GLP-1 Receptor Agonist
GLP-1 has a variety of anti-diabetic effects. However, native GLP-1 is not suitable for therapy of diabetes due to its short half-life (t1/2<2 min). To circumvent this, we developed a long-lasting GLP-1 receptor agonist by the fusion of GLP-1 with human IgG2 Fc (GLP-1/hIgG2). ELISA-based receptor binding assay demonstrated that GLP-1/hIgG2 had high binding affinity to the GLP-1R in INS-1 cells ...
متن کاملA β-peptide agonist of the GLP-1 receptor, a class B GPCR.
Previous work has shown that certain β(3)-peptides can effectively mimic the side chain display of an α-helix and inhibit interactions between proteins, both in vitro and in cultured cells. Here we describe a β(3)-peptide analog of GLP-1, CC-3(Act), that interacts with the GLP-1R extracellular domain (nGLP-1R) in vitro in a manner that competes with exendin-4 and induces GLP-1R-dependent cAMP s...
متن کاملExpression and Characterization of a Potent Long-Acting GLP-1 Receptor Agonist, GLP-1-IgG2σ-Fc
Human GLP-1 (glucagon-like peptide-1) can produce a remarkable improvement in glycemic control in patients with type 2 diabetes. However, its clinical benefits are limited by its short half-life, which is less than 2 min because of its small size and rapid enzymatic inactivation by dipeptidyl peptidase IV. We engineered GLP-1-IgG2σ-Fc, a 68-kDa fusion protein linking a variant human GLP-1 (A8G/...
متن کاملserum levels of glucagon-like peptide (glp)-1 and glp-2 in patients with hashimoto’s thyroiditis
background: the influence of hashimoto’s thyroiditis (ht) with subclinical hypothyroidism or euthyroid status on the alteration of glucagon-like peptide (glp)-1 and glp-2 levels remains uncertain. materials and methods: twenty-four untreated ht patients with subclinical hypothyroidism, 24 euthyroid ht patients, and 24 age- and gender-matched controls were enrolled in the study. the levels of gl...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Scientific Reports
سال: 2018
ISSN: 2045-2322
DOI: 10.1038/s41598-018-24359-2